| |
| |
|
| Insider
Information: |
Maynard Ryan D |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
21,000 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$100,424 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
21,000 |
|
|
| Total
Value |
$100,424 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 9.6%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Rigel Pharmaceuticals Inc |
RIGL |
EVP & CFO |
2017-11-03 |
0 |
2012-08-07 |
0 |
Premium* |
|
|
Iovance Biotherapeutics Inc |
IOVA |
Director |
2022-05-31 |
7,500 |
2022-05-31 |
0 |
Premium* |
|
|
Cara Therapeutics, Inc. |
CARA |
|
2024-02-01 |
13,500 |
2024-02-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
15 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CARA |
Cara Therapeutics, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,500 |
13,500 |
0 |
- |
|
| CARA |
Cara Therapeutics, Inc. |
CHIEF FINANCIAL OFFICER |
• – – |
2023-02-08 |
4 |
AS |
$0.53 |
$2,909 |
D/D |
(5,488) |
8,012 |
0 |
% |
|
| IOVA |
Iovance Biotherapeutics I... |
Director |
– • – |
2022-05-31 |
4 |
B |
$6.75 |
$50,588 |
D/D |
7,500 |
7,500 |
2.39 |
% |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2017-11-03 |
4 |
AS |
$3.90 |
$390,000 |
D/D |
(100,000) |
0 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2017-11-03 |
4 |
OE |
$2.14 |
$214,000 |
D/D |
100,000 |
100,000 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-09-12 |
4/A |
S |
$10.67 |
$248,560 |
D/D |
(23,302) |
0 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-09-12 |
4/A |
OE |
$6.49 |
$151,230 |
D/D |
23,302 |
23,302 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-09-10 |
4 |
OE |
$6.49 |
$114,133 |
D/D |
17,586 |
17,586 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-09-10 |
4 |
S |
$10.52 |
$184,927 |
D/D |
(17,586) |
0 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-09-07 |
4 |
S |
$10.67 |
$248,560 |
D/D |
(23,302) |
0 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-09-07 |
4 |
OE |
$6.49 |
$151,230 |
D/D |
23,302 |
23,302 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-09-07 |
4 |
S |
$10.55 |
$359,960 |
D/D |
(34,112) |
0 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-09-07 |
4 |
OE |
$6.49 |
$221,387 |
D/D |
34,112 |
34,112 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-08-07 |
4 |
S |
$10.60 |
$18,041 |
D/D |
(1,700) |
0 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-08-07 |
4 |
OE |
$6.49 |
$11,033 |
D/D |
1,700 |
1,700 |
0 |
- |
|
15 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
